News
CONGRATULATIONS: Wakefield Asset Management named Top Gun Manager 2Q16

Wakefield Asset Management  Named Top Gun Manager - Englewood, CO, August 18, 2016 – Wakefield Asset Management, LLLP, is pleased to announce that our Wakefield Large Cap Equity Portfolio was named as a Top Gun by Informa Investment Solutions’ PSN manager database in three categories for performance returns for the quarter ended June 30, 2016. The Large Cap Portfolio is managed by G. Todd Gervasini, the President and Chief Investment Officer for Wakefield Asset Management.  

The awards for the Large Cap Equity Portfolio include:

 Top ten performer within US Core Equity Universe based on 3 year performance return and correlation to the benchmark (4 Stars)

 Top ten performer within Large Core Equity Universe based on 3 year performance return and correlation to the benchmark (4 Stars)

 Top ten performer within Large Core Equity Universe based on 3 year performance return (3 Stars) 

Wakefield Asset Management, LLLP is a bottom-up research driven firm offering a unique investment strategy that stands apart from the mainstream investment community.  Focusing on proprietary investment techniques, Wakefield captures inefficiencies over time using a highly disciplined and technologically advanced process for research, security selection, implementation, and monitoring. Headquartered near Denver, Colorado, Wakefield is a 100% employee owned SEC registered investment advisor managing separately managed accounts, primarily for high-net worth individuals, family offices, and institutions. 
 
Past performance is not indicative of future results. Investing involves multiple risks, including but not limited to the risk of the permanent loss of capital.  Adviser makes no guarantees or promissory representations as to the performance of any investment.  Wakefield Large Cap Equity composite returns are used in the PSN investment manager questionnaire. Actual results may differ from the composite results depending on the size of the account, investment objectives, restrictions, transaction and related costs, the inception and date of the account and other factors.  
 
About Informa Investment Solutions’ PSN Top Guns List:  Utilizing a proprietary blend of Informa Investment Solutions’ top priority performance screens, PSN Top Guns ranks products in six proprietary star categories in over 50 universes. This is a highly anticipated quarterly ranking and is widely used by institutional asset managers and investors. The complete list of PSN Top Guns and an overview of the methodology can be located on http://www.informais.com/resources/psn-top-guns . For more details on the methodology behind the PSN Top Guns Rankings contact Ruth Calderon at ruth.calderon@informais.com.  
 
About Informa Investment Solutions: A market leader in intelligence and software solutions for investment professionals and financial institutions of all sizes, Informa Investment Solutions offers a robust set of analytics and tools to help you grow and retain your business. With a nearly 40-year history, Informa Investment Solutions is part of Informa PLC, a leading business-to-business knowledge provider serving International markets. Informa Investment Solutions has set the standard for providing turnkey and customizable applications for performing manager searches, building wealth plans, and producing client reports and investment marketing materials for companies worldwide.
 
For more information, please visit http://www.informais.com/ and follow https://twitter.com/InformaInvest.  
 
The US Core Universe is comprised 336 managers, with 787 strategies.
 
The Large Core Equity universe is comprised of 219 managers with 371 strategies.
 
The peer groups were created using the information collected through the PSN investment manager questionnaire and uses only gross of fee returns. PSN Top Guns investment managers must claim that they are GIPs compliant.
 
5 STAR CATEGORY: Products must have an R Squared of 0.80 or greater relative to the style benchmark for the recent five year period. Moreover, products must have returns greater than the style benchmark for the three latest three year rolling periods. After that we select only the products which standard deviation for the five year period is equal or less than the median standard deviation for the peer group. The top ten returns for the latest three year period then become the TOP GUNS.
 
4 STAR CATEGORY: Products must have an R Squared of 0.80 or greater relative to the style benchmark for the recent five year period. Moreover, products must have returns greater than the style benchmark for the three latest three year rolling periods. The top ten returns for the latest three year period then become the TOP GUNS.
 
3 STAR CATEGORY: Top ten performers are strictly based on returns for three year period.
 
2 STAR CATEGORY: Top ten performers based on returns for the one year period.
 
1 STAR CATEGORY:  Top ten performers based on returns for the quarter. 

CONGRATULATIONS - WAKEFIELD ASSET MANAGEMENT Named Top Gun Manager

FOR IMMEDIATE RELEASE:

Englewood, CO, February 2, 2016 – Wakefield Asset Management, LLLP, is pleased to announce that our Wakefield Large Cap Equity Portfolio was named as a Top Gun by Informa Investment Solutions’ PSN manager database in five categories for performance returns for the quarter ended December 31, 2015. The Large Cap Portfolio is managed by G. Todd Gervasini, the President and Chief Investment Officer for Wakefield Asset Management.

The awards for the Large Cap Equity Portfolio include:
 Top ten performer within US Core Equity Universe based on 3 year performance return and correlation to the benchmark (4 Stars)
 Top ten performer within US Core Equity Universe based on 1 year performance return (2 Stars)
 Top ten performer within Large Core Equity Universe based on 3 year performance return and correlation to the benchmark (4 Stars)
 Top ten performer within Large Core Equity Universe based on 3 year performance return (3 Stars)
 Top ten performer within Large Core Equity Universe based on 1 year performance return (2 Stars)
 
Wakefield Asset Management, LLLP is a bottom-up research driven firm offering a unique investment strategy that stands apart from the mainstream investment community. Focusing on proprietary investment techniques, Wakefield captures inefficiencies over time using a highly disciplined and technologically advanced process for research, security selection, implementation, and monitoring. Headquartered near Denver, Colorado, Wakefield is a 100% employee owned SEC registered investment advisor managing separately managed accounts, primarily for high-net worth individuals, family offices, and institutions.
 
Past performance is not indicative of future results. Investing involves multiple risks, including but not limited to the risk of the permanent loss of capital. Adviser makes no guarantees or promissory representations as to the performance of any investment. Wakefield Large Cap Equity composite returns are used in the PSN investment manager questionnaire. Actual results may differ from the composite results depending on the size of the account, investment objectives, restrictions, transaction and related costs, the inception and date of the account and other factors.
 
About Informa Investment Solutions’ PSN Top Guns List: Utilizing a proprietary blend of Informa Investment Solutions’ top priority performance screens, PSN Top Guns ranks products in six proprietary star categories in over 50 universes. This is a highly anticipated quarterly ranking and is widely used by institutional asset managers and investors. The complete list of PSN Top Guns and an overview of the methodology can be located on http://www.informais.com/resources/psn-top-guns . For more details on the methodology behind the PSN Top Guns Rankings contact Ruth Calderon at ruth.calderon@informais.com.

Author backs Biblically Responsible Investing

 

Author backs Biblically Responsible Investing

Tracy Simmons
 
 

Graham
(Full-size photo)

 

In his debut book “Investing with Integrity,” Spokane-based financial adviser Loran Graham argues that Christians can and should honor God through their fiscal investments.

The book emphasizes the national movement of Biblically Responsible Investing (BRI), which holds that believers’ investment choices should align with their values.

According to the Christian Investment Forum, BRI is a term coined about 15 years ago to describe an approach to investing assets in a way that aligns with an investor’s faith and biblical beliefs.

“The idea is that you look at what activities, products or services a company provides and what impact that has on others in society,” Graham said recently.

If a company has caused physical or mental harm by exploiting a gambling addiction, for example, then that’s not a company a Christian should invest in, Graham said.

John Siverling, executive director of the Christian Investment Forum, said being a Christian investor doesn’t have to mean investing strictly in Christian companies but in those that meet social and faith-based criteria.

Graham said many people own stocks through their mutual funds but don’t know what stocks they own. A financial adviser, Graham said, can help people have more control over that.

“It doesn’t make someone a better Christian to have a personal portfolio,” Graham said. “It’s not an act of self-righteousness. I’m most passionate about the larger population, which is to have every Christian believe and invest this way, which would have a significant, collective impact on the capital market.”

In the book Graham, 37, writes that Biblically Responsible Investing is also about financial gain and leaving a legacy.

“We want to support companies that are making a positive impact, but at the same time we can’t forget the reason for investing, which is to aim for a return on investment and to meet our individual family needs,” he said.

He said Christian investors have an opportunity to train the next generation of stewards by modeling behaviors and teaching children about compassion in the marketplace.

Graham and his wife, Kjirstin, have 4-year-old twins. Graham is also a certified public accountant and serves on a number of nonprofit boards, including the YMCA of the Inland Northwest, Vanessa Behan Crisis Nursery and the Inland Northwest Community Foundation.

He said he felt now was the time to publish his book because there seems to be an emerging awareness about conscientious spending.

“I really feel like we’re on the cusp of a much larger movement that’s just getting underway. You can see it even with millennials, who are very much cause-driven,” he said. “It’s exciting. If more investors start asking for this way of investing, then that will put the pressure on firms to offer it. If we change the way Wall Street operates and does business, there really is the potential to change the world.”

Rob West, president of Kingdom Advisors, a nationwide community of Christian financial professionals, said there’s an interest in faith-based investing because money is a reflection of one’s heart.

“When we invest in a company, or give to an organization, we’re more interested in what they’re doing. Our heart follows the money,” he said. “Money is a barometer of our heart. And it goes all the way back to the Bible (Matthew 6:21).”


CONGRATULATIONS - EVENTIDE GILEAD FUND Best Performing Midcap Growth Mutual Fund for 2014

 

Eventide Gilead Fund Best Performing Midcap Growth Mutual Fund for 2014


JANUARY 20, 2015

BOSTON, MA - (Marketwire - Jan 20, 2015) - The Eventide Gilead Fund (NASDAQ: ETILX), a mutual fund practicing values-based investing, was the best performing midcap growth mutual fund for 2014 according to independent investment research provider Morningstar. With a one-year total return of 18.08%, the Eventide Gilead Fund had the highest one-year performance in the Midcap Growth category by Morningstar out of 746 funds, for the period ending December 31, 2014.

The Wall Street Journal also recognized the Eventide Gilead Fund for 2014 performance, naming it a "Category King" in the Midcap Growth category -- an award honoring the top 10 mutual funds in each equity category in one-year total performance. The Gilead Fund was ranked #1 out of 421 midcap growth funds by the WSJ Category King for the one-year period ending December 31, 2014.

The Eventide Gilead Fund also finished the year with an impressive sweep of long-term rankings in Morningstar's Midcap Growth category: the No-load Class shares ranking in the top 1% of its peer group for each of the one-, three-, and five-year time periods, for total performance. Overall, the Gilead Fund is rated five-stars out of five by Morningstar, using a methodology that considers both performance and risk factors.



The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based Registered Investment Advisor with a values-based approach to investing. Eventide CEO Robin John commented: "We view the Eventide Gilead Fund outperformance in 2014 and since inception as validation of our investment philosophies of the value of expertise over general knowledge, that truly wise investing means partnering with companies that excel at creating value for others, and a belief that risk management should rely on a wide range of rigorous data."

Eventide Funds CIO and Lead Portfolio Manager of the Eventide Gilead Fund Finny Kuruvilla, MD PhD commented on two of the Fund's best performers in 2014: "Legitimate, market-disrupting innovation will consistently be rewarded. Our investments in companies like Agios (AGIO) and bluebird bio (BLUE) were rewarded as these companies combined excellence in biomedical research with disciplined execution in clinical trials. We continue to believe that innovation in biotechnology is a secular trend that has much farther to go."

Eventide also manages the Eventide Healthcare & Life Sciences Fund (NASDAQ: ETNHX), a Health sector fund. With a median market cap of just $1.22B and 71.33% percent of the net assets invested in the Biotech & Pharma Industry (as of December 31, 2014), the Eventide Healthcare & Life Sciences Fund focuses on investing in high innovation, small, early-development stage biotechnology companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products. The Healthcare & Life Sciences Fund finished its 2014 year in the top one-third of its Morningstar peer group, the Health Category, ranked by total return, out of 126 funds.



When asked what 2015 holds for investors, Dr. Kuruvilla said, "The combination of weak investor sentiment (a contrarian positive signal), reasonable valuations, and favorable leading indicators make us constructive on the market for 2015. While the collapse in the price of oil and the decline in yield on the 10-year Treasury may be alarming, these signals are partially offset by their own effects: cheaper oil means additional money in the consumer's pocket and lower interest rates results in more affordable mortgages which can sustain a recovery in housing."

As of December 31, 2014, the Eventide Gilead Fund had $986.62 million in net assets, and the Eventide Healthcare & Life Sciences Fund had $149.28 million in net assets.

The following tables show the performance of the Eventide Funds since inception:

 

As of 12/31/2014

1 year return

3 year annualized return

5 year annualized return

Since inception (07/08/2008) annualized return

Eventide Gilead Fund

17.86%

28.65%

20.39%

17.77%

Russell Mid-Cap Growth Total Return Index

11.90%

20.71%

16.94%

11.05%

S&P 500 Total Return Index

13.69%

20.41%

15.45%

10.08%

 

As of 12/31/2014

1 year return

Since inception (12/27/2012) annualized return

Eventide Healthcare & Life Sciences Fund

29.11%

44.55%

Healthcare Blended Index

17.44%

33.36%

S&P 500 Total Return Index

13.69%

22.90%

 

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the funds' prospectus for more information regarding the funds' fees and expenses. Eventide Gilead Fund performance shown is for No-load Class shares and the Eventide Healthcare & Life Sciences Fund performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

Eventide Gilead Fund expenses: Total Expenses 1.45%. Eventide Healthcare & Life Sciences Fund expenses: Gross Expenses 1.70%; Net Expenses 1.64%. The advisor has contractually agreed to waive fees and/or reimburse expenses of the Eventide Healthcare & Life Sciences Fund through 31 October 2015.

Morningstar, Inc. All rights reserved. Morningstar is an independent provider of financial information. Morningstar percentile rankings are based on total return without sales charge relative to all share classes of mutual funds with similar objectives and determined by Morningstar. Past performance or ranking is not indicative of future results. Morningstar rating given is an Overall Rating, against 583 US Mid-Cap Growth Funds for the 5yr period, as of 12/31/2014, and 643 Funds for the 3yr period, based on risk-adjusted total return. Ratings are determined monthly and subject to change. The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics. The top 10% of the funds in a rating universe receive five stars, the next 22.5% receive four stars, the next 35% receive three stars, the next
22.5% receive two stars and the bottom 10% receive one star. Past performance or ranking is not indicative of future results. Eventide Gilead Fund Morningstar 5yr percentile rank was out of 583 funds; 3yr rank was out of 643 funds; 1yr rank was out of 746 funds.

 

Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only.

Agios (AGIO) was 2.54% of the Eventide Gilead Fund and 2.58% of Eventide Healthcare & Life Sciences Fund net assets, as of December 31, 2014, and subject to change. bluebird bio, Inc (BLUE) was 2.96% of Eventide Gilead Fund and 4.37% of Eventide Healthcare & Life Sciences Fund net assets, as of December 31, 2014, and subject to change.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. These indexes are not investment products available for purchase.

Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less
efficient trading markets, political instability and differing auditing and legal standards. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

 

An investor should consider the Funds' investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds' prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the Fund, toll free at 877-771-EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Fund Contact:
Jason Myhre, 877-771-EVEN (3836)

 

 

--


Archives